POSA145 Budget Impact of Zanubrutinib to Treat Relapsed or Refractory Marginal Zone Lymphoma from a Payer Perspective in the United States
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.288
https://www.valueinhealthjournal.com/article/S1098-3015(21)02083-0/fulltext
Title :
POSA145 Budget Impact of Zanubrutinib to Treat Relapsed or Refractory Marginal Zone Lymphoma from a Payer Perspective in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02083-0&doi=10.1016/j.jval.2021.11.288
First page :
Section Title :
Open access? :
No
Section Order :
11062